| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―May―01 |
Nationwide survey of practice after COVID-19 pandemic conducted in medical schools","医学部薬理学関連講座におけるCOVID-19パンデミック後の実習に関する全国実態調査の結果から |
Masaki Mogi, Shung Liu |
| 2 |
[GO] |
2022―Oct―31 |
A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs |
Daiki Ousaka, Masahiro Nishibori |
| 3 |
[GO] |
2022―Jun―30 |
Treatment of COVID-19 |
Kazuhiro Yatera |
| 4 |
[GO] |
2022―Feb―28 |
Role of ACE2 in COVID-19 |
Yumiko Imai |
| 5 |
[GO] |
2022―Feb―28 |
Engineered ACE2 receptor has a potential for a new therapy of COVID-19 |
Yumi Itoh, Hajime Enatsu, Akira Takada, Toru Okamoto |
| 6 |
[GO] |
2022―Feb―28 |
Development of COVID-19 drugs using human iPS cell technology |
Shigeru Yamada, Yasunari Kanda |
| 7 |
[GO] |
2022―Feb―28 |
Eco-pharma research aimed at developing COVID-19 therapeutic agent |
Yuri Kato, Kazuhiro Nishiyama, Akiyuki Nishimura, Motohiro Nishida |
| 8 |
[GO] |
2022―Feb―28 |
Drug screening for COVID-19 using supercomputer “Fugaku” |
Yasushi Okuno |
| 9 |
[GO] |
2021―Dec―31 |
COVID-19 drug candidate pipeline, an overview |
Hiroyuki Sugiyama |
| 10 |
[GO] |
2021―Dec―31 |
Remdesivir for COVID-19 |
Yasuhisa Fujita |
| 11 |
[GO] |
2021―Dec―31 |
Drug repositioning to combat COVID-19 using artificial intelligence system |
Norihisa Shindo, Hiroyoshi Toyoshiba |
| 12 |
[GO] |
2021―Dec―31 |
Contribution to development of remedies for COVID-19: focusing on Eritoran |
Kappei Tsukahara |
| 13 |
[GO] |
2021―Oct―31 |
Responses to the COVID-19 pandemic and its impacts on pharmacology education in the universities and colleges in Japan: nationwide emergency survey jointly conducted by the Physiological Society of Japan and the Japanese Pharmacological Society |
Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Satoshi Tanaka, Masabumi Minami |
| 14 |
[GO] |
2021―Apr―30 |
Therapeutic potential of nanocurcumin in COVID-19 |
Koji Teshima |
